LIVECAST Markets Briefs Calendar Search

Research

AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Briefs Calendar Search AI Market Assistant Instrument directory Macro Politics Prediction Markets News Archive Account

Live News REGULATION FLASH L impact Sep 29, 2026, 01:46 PM UTC

Orexo Resubmits NDA For Izipry To FDA

Orexo AB OMXSTO:ORX

SquawkNews Newsroom

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

ORX

Related stories

FTC Solar, Inc. (FTCI) Signs MoU With Linxon, Hitachi Energy to Pursue Utility-Scale Solar/BESS FTC Solar signed a Memorandum of Understanding with Linxon and Hitachi Energy to jointly pursue and deliver utility-scale solar and BESS projects, with Linxon as EPC integrator, Hi L impact | REGULATION | Sep 29, 2026, 02:08 PM UTC Linxon, Hitachi Energy And FTC Solar Announce Strategic Collaboration Linxon L impact | REGULATION | Sep 29, 2026, 02:07 PM UTC Linxon, Hitachi Energy and FTC Solar Announce Strategic Collaboration to Accelerate Utility-Scale Renewable Energy and Grid Infrastructure Development L impact | REGULATION | Sep 29, 2026, 02:02 PM UTC Orexo resubmits IZIPRY naloxone nasal powder NDA to FDA for opioid overdose treatment Orexo said it completed its FDA resubmission of the IZIPRY (naloxone nasal powder) NDA on Sept. 29, 2026, addressing deficiencies cited in a July 2024 complete response letter. FDA M impact | REGULATION | Sep 29, 2026, 01:46 PM UTC UK Prime Minister Andy Burnham vows to create a national care service free at use Burnham told the Labour Party conference the national care service would be free at the point of use and funded so care charges would not be taken from a basic state pension. M impact | REGULATION | Sep 29, 2026, 01:45 PM UTC Orexo AB (publ.) (ORX) Resubmits IZIPRY NDA to FDA Orexo resubmitted its NDA for IZIPRY (naloxone nasal powder) to the FDA on Sep 29, 2026, addressing a 2024 CRL. FDA acceptance and a review timeline are expected in the coming week L impact | REGULATION | Sep 29, 2026, 01:45 PM UTC

SQUAWK/NEWS

Live financial news for traders. Read the headline on screen or hear it through LiveCast while you stay on the trade.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

Product

Open LiveCast
Plans & Pricing
Institutional API
How LiveCast Works
Live Markets
Session Briefs
RSS Feed
Calendar
Search
Instrument directory

Research

Macro
Politics
Prediction Markets
AI Market Assistant
News Archive

For Traders

Market Movers
US Stocks
Why News Moves Markets
News for Traders
How to Trade the News
What Is an Audio Squawk?
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.